SCHEMBL24143743

SCHEMBL24143743

CCn1cc(CCN)c2ccc(-c3ccncc3)cc21

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ NR1D1 P20393 8/20 0.50
▸ METAP2 P50579 3/20 0.40
▸ HTR2A P28223 1/20 0.38
▸ CHEK1 O14757 3/20 0.38
▸ CYP19A1 P11511 1/20 0.37
▸ TBXAS1 P24557 1/20 0.37
▸ ROCK2 O75116 1/20 0.36
▸ CDK1 P06493 1/20 0.36
▸ PRKACA P17612 1/20 0.36
▸ CDK2 P24941 1/20 0.36
▸ CSNK1D P48730 1/20 0.36
▸ GSK3A P49840 1/20 0.36
▸ CDK5 Q00535 1/20 0.36
▸ PRKCD Q05655 1/20 0.36
▸ ROCK1 Q13464 1/20 0.36
▸ CDC42BPA Q5VT25 1/20 0.36
▸ MARK2 Q7KZI7 1/20 0.36
▸ AAK1 Q2M2I8 1/20 0.36
▸ HTR6 P50406 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24144465 0.90 NR1D1 (0.48) NR1D1METAP2HTR2ACHEK1AAK1
SCHEMBL24142979 0.86 NR1D1 (0.67) NR1D1
SCHEMBL24143664 0.84 NR1D1 (0.44) NR1D1METAP2HTR2ACHEK1TBXAS1
SCHEMBL24143870 0.84 NR1D1 (0.46) NR1D1METAP2HTR2ACHEK1AAK1
SCHEMBL24143542 0.84 NR1D1 (0.53) NR1D1HTR2AAAK1
SCHEMBL24143036 0.84 HTR2A (0.54) NR1D1METAP2HTR2ACHEK1AAK1
SCHEMBL24143866 0.83 NR1D1 (0.50) NR1D1METAP2CHEK1AAK1
SCHEMBL24144078 0.83 NR1D1 (0.48) NR1D1METAP2CHEK1
SCHEMBL24144070 0.83 HTR6 (0.54) NR1D1CYP19A1HTR6
SCHEMBL24143742 0.81 NR1D1 (0.47) NR1D1METAP2HTR2ACHEK1AAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2021263278-A1 REV-ERB AGONISTS FOR THE TREATMENT OF TH17-MEDIATED INFLAMMATORY DISORDERS THE SCRIPPS RESEARCH INSTITUTE (US) 2021-12-30 — — WO disclosed
Send feedback